BidaskClub Downgrades TransMedics Group (NASDAQ:TMDX) to Sell

Share on StockTwits

TransMedics Group (NASDAQ:TMDX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday, BidAskClub reports.

Several other equities analysts have also recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of TransMedics Group from $22.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, March 4th. Zacks Investment Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. TransMedics Group has a consensus rating of “Hold” and an average target price of $27.40.

NASDAQ TMDX opened at $12.89 on Friday. TransMedics Group has a twelve month low of $10.10 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.51 and a current ratio of 6.21. The stock has a market cap of $278.19 million and a price-to-earnings ratio of -2.02. The firm’s 50 day moving average price is $16.04 and its two-hundred day moving average price is $18.56.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.04). The business had revenue of $6.06 million for the quarter, compared to analysts’ expectations of $6.51 million. On average, research analysts forecast that TransMedics Group will post -1.45 EPS for the current fiscal year.

In other news, insider Tamer I. Khayal sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the insider now directly owns 51,076 shares in the company, valued at approximately $1,022,541.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Several institutional investors have recently bought and sold shares of the company. Credit Suisse AG grew its holdings in shares of TransMedics Group by 47.6% during the 4th quarter. Credit Suisse AG now owns 1,131,845 shares of the company’s stock valued at $21,516,000 after acquiring an additional 365,271 shares in the last quarter. Sandhill Capital Partners LLC grew its holdings in shares of TransMedics Group by 48.4% during the 4th quarter. Sandhill Capital Partners LLC now owns 736,175 shares of the company’s stock valued at $13,995,000 after acquiring an additional 240,149 shares in the last quarter. Zimmer Partners LP grew its holdings in shares of TransMedics Group by 2.4% during the 3rd quarter. Zimmer Partners LP now owns 551,284 shares of the company’s stock valued at $13,093,000 after acquiring an additional 12,759 shares in the last quarter. Emerald Advisers LLC grew its holdings in shares of TransMedics Group by 116.6% during the 4th quarter. Emerald Advisers LLC now owns 451,542 shares of the company’s stock valued at $8,584,000 after acquiring an additional 243,034 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its holdings in shares of TransMedics Group by 118.8% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 429,868 shares of the company’s stock valued at $8,172,000 after acquiring an additional 233,358 shares in the last quarter. Institutional investors and hedge funds own 70.70% of the company’s stock.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Featured Article: Insider Trading

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hammerson  Sets New 52-Week Low at $0.67
Hammerson Sets New 52-Week Low at $0.67
G4S/ADR  Reaches New 12-Month Low at $4.29
G4S/ADR Reaches New 12-Month Low at $4.29
KERRY GRP PLC/S  Hits New 52-Week Low at $98.03
KERRY GRP PLC/S Hits New 52-Week Low at $98.03
Johnson Matthey  Reaches New 52-Week Low at $39.70
Johnson Matthey Reaches New 52-Week Low at $39.70
Minebea Mitsumi  Sets New 52-Week Low at $25.87
Minebea Mitsumi Sets New 52-Week Low at $25.87
British Land  Sets New 52-Week Low at $3.72
British Land Sets New 52-Week Low at $3.72


© 2006-2020 Ticker Report